RxDoctor Payments Data

Justin Smith, MD

Clinical Cardiac Electrophysiology · Pensacola, FLNPI 1245556307

Payments from drug & device makers

$10,244in general payments, 2019–2025

Across 269 payments — averaging $38.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$1K
  • Biosense Webster, Inc.$1K
  • Abbott$642
  • E.r. Squibb & Sons, L.L.C.$504
  • Atricure, Inc.$288
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$3,43834%
  • Food & beverage$6,79266%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,244 in reported general payments places this provider in the 15th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$446,551
Medicare patients
1,784
Services billed
6,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban322$344,329
EntrestoSacubitril/Valsartan71$92,975
XareltoRivaroxaban98$85,372
FarxigaDapagliflozin Propanediol58$58,978
JardianceEmpagliflozin26$37,149
MultaqDronedarone Hcl45$33,879
Repatha SureclickEvolocumab21$17,245
Flecainide Acetate58$2,853
Metoprolol Succinate191$2,421
Ranolazine ErRanolazine22$1,811
Amiodarone Hcl42$1,470
ClopidogrelClopidogrel Bisulfate133$1,367
Carvedilol110$1,211
Diltiazem 24hr Er (La)Diltiazem Hcl14$1,128
Colchicine54$1,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$162$344,329322 claims
NovartisEntresto$174$92,97571 claims
Johnson & JohnsonXarelto$231$85,37298 claims
AstraZenecaFarxiga$160$58,97858 claims
Boehringer IngelheimJardiance$92$37,14926 claims
Sanofi-aventis U.S. LLCMultaq$153$33,87945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →